Herzschrittmachertherapie und Elektrophysiologie最新文献

In 2021, about 75,000 persons in Germany died unnaturally or due to unexplained reasons. As a consequence, there are difficulties in more precisely identifying the time, cause and circumstances of death. Nevertheless, clarification is crucial not only from the clinical perspective, but these data are of considerable importance in the context of investigative procedures as they can be used to answer numerous legally relevant questions. Cardiac implantable devices (CIED) are of vital importance in the treatment of cardiac arrhythmias. In 2020 about 100,000 patients underwent CIED implantation in Germany. Therefore, CIED are present in a relevant proportion of the deceased mentioned above. The valuable source of information represented by postmortal CIED interrogation has been shown in numerous studies. Nevertheless, postmortal CIED interrogation is not routinely performed in the context of forensic medical examinations for reasons of practicability. This article summarizes benefits and limitations of postmortal CIED interrogation from the perspective of forensic medicine and cardiology and gives a recommendation for realization.

Echocardiography plays a key role in planning and guidance of electrophysiological procedures. After exclusion of structural heart disease, echocardiography provides insight into the extent of left atrial remodeling by determining left atrial metrics. This "biomarker" is associated with the risk of new-onset atrial fibrillation and predictive of atrial fibrillation recurrence after ablation. Transesophageal echocardiography is necessary to exclude left atrial thrombi and is able to guide a transseptal puncture. In case of a rare but life-threatening cardiac tamponade, an echocardiographic-guided pericardiocentesis ensures quick and effective treatment. Left ventricular ejection fraction and deformation analysis determined by echocardiography are established methods for risk stratification in patients with systolic dysfunction and used to guide pharmacological and device therapy.

Sixty-five years ago, the first pacemakers were implanted. Swedish developments paved the way for implantation of the first epicardial pacemaker with a rechargeable battery unit; however, there was a battery defect within 3 h. Further developments in the USA allowed for the first transvenous, endocardial lead to be implanted with an external pacemaker battery. Following these pioneering implantations, further improvements of the battery and electrical elements and also of lead technology (flexibility and fixation mechanism) allowed the implantation of pacemaker systems similar to those we still implant today.

Background: Smartphone apps are increasingly utilised by patients and physicians for medical purposes. Thus, numerous applications are provided on the App Store platforms.

Objectives: The aim of the study was to establish a novel, expanded approach of a semiautomated retrospective App Store analysis (SARASA) to identify and characterise health apps in the context of cardiac arrhythmias.

Materials and methods: An automated total read-out of the "Medical" category of Apple's German App Store was performed in December 2022 by analysing the developer-provided descriptions and other metadata using a semiautomated multilevel approach. Search terms were defined, based on which the textual information of the total extraction results was automatically filtered.

Results: A total of 435 of 31,564 apps were identified in the context of cardiac arrhythmias. Of those, 81.4% were found to deal with education, decision support, or disease management, and 26.2% (additionally) provided the opportunity to derive information on heart rhythm. The apps were intended for healthcare professionals in 55.9%, students in 17.5%, and/or patients in 15.9%. In 31.5%, the target population was not specified in the description texts. In all, 108 apps (24.8%) provided a telemedicine treatment approach; 83.7% of the description texts did not reveal any information on medical product status; 8.3% of the apps indicated that they have and 8.0% that they do not have medical product status.

Conclusion: Through the supplemented SARASA method, health apps in the context of cardiac arrhythmias could be identified and assigned to the target categories. Clinicians and patients have a wide choice of apps, although the app description texts do not provide sufficient information about the intended use and quality.

ChatGPT, a chatbot based on a large language model, is currently attracting much attention. Modern machine learning (ML) architectures enable the program to answer almost any question, to summarize, translate, and even generate its own texts, all in a text-based dialogue with the user. Underlying technologies, summarized under the acronym NLP (natural language processing), go back to the 1960s. In almost all areas including medicine, ChatGPT is raising enormous hopes. It can easily pass medical exams and may be useful in patient care, diagnostic and therapeutic assistance, and medical research. The enthusiasm for this new technology shown even by medical professionals is surprising. Although the system knows much, it does not know everything; not everything it outputs is accurate either. Every output has to be carefully checked by the user for correctness, which is often not easily done since references to sources are lacking. Issues regarding data protection and ethics also arise. Today's language models are not free of bias and systematic distortion. These shortcomings have led to calls for stronger regulation of the use of ChatGPT and an increasing number of similar language models. However, this new technology represents an enormous progress in knowledge processing and dissemination. Numerous scenarios in which ChatGPT can provide assistance are conceivable, including in rhythmology. In the future, it will be crucial to render the models error-free and transparent and to clearly define the rules for their use. Responsible use requires systematic training to improve the digital competence of users, including physicians who use such programs.

A number of publications have claimed that Mobitz type II second-degree atrioventricular (AV) block can occur during sleep apnea. None has provided a definition of type II block used in the articles, and representative electrocardiograms have been generally missing. Despite these reports, the existence of type II AV block during sleep must remain questionable.

There is increasing knowledge of the genetic basis of distinct cardiac pathologies that are related to ventricular tachyarrhythmias (VT) and sudden cardiac death (SCD). The identification of genes responsible for inherited cardiac diseases has led to the organization of cardiogenetic consultations in many countries worldwide. The 2022 European Society of Cardiology (ESC) guidelines for the management of patients with ventricular arrhythmias and the prevention of SCD and the international 2022 Expert Consensus Statement on the state of genetic testing for cardiac diseases emphasize the importance of genetic testing in cardiology practice along with appropriate information provision to affected individuals and their relatives. However, the context of genetic examination raises particular ethical, practical (including economic or financial), and legal challenges. This review aims to elucidate practical considerations related to legal aspects relevant for the evaluation of patients presenting with VT in Germany.

Since 2016, quarterly telemedical remote monitoring of patients with an implanted defibrillator or cardiac resynchronization therapy (CRT) system is part of the Einheitlichen Bewertungsmaßstab (EBM, physician's fee schedule) and is the first telemedical service to be reimbursed in German cardiology. Many publications like the TIM-HF2 or the InTime trial have shown a significant benefit for different endpoints in patients with advanced heart failure. Therefore, the German Society of Cardiology (DGK) has published different recommendations that emphasize an obvious indication of telemedical care with daily control of implantable cardioverter-defibrillator (ICD) information, parameters like blood pressure and weight, and telemedical counselling of patients with heart failure with reduced ejection fraction. This recommendation is also part of the guidelines of the European Society of Cardiology (ESC) published in 2021. It has a level IIb for patients with heart failure. In December 2020 the "Gemeinsame Bundesausschuss" (G-BA) decided to accept telemonitoring as a diagnostic tool and treatment option for patients with heart failure. This service of physicians became part of the EBM and ever since may be offered to patients. This development is accompanied with many questions regarding a physician's accountability, protection of data privacy, and also regarding the structures given by the G‑BA and the "Kassenärztlichen Vereinigungen" (KV). Thus, this paper tries to give an overview of these topics. It will also provide a critical discussion of these structures and their legal foundation because there are many constraints that need to be taken into consideration as a cardiologist. These constraints may ultimately hinder the expansion of this service to patients in Germany.

Patients with statutory health insurance in Germany have the right to obtain a second opinion at the expense of their health insurance in addition to that of their primary practitioner before certain procedures are carried out. This gives rise to various legal obligations and questions on the part of both the practitioner and the second opinion provider. This article outlines, based on the legal situation, which obligations exist for both practitioners and second opinion providers, and who is suitable to provide a second opinion. Focus is placed on informing patients about the possibility of obtaining a second opinion. On the other hand, it explains which requirements second opinion providers have to fulfill and which duties are incumbent on them.